Clinical outcomes following ide-cel CAR-T therapy
| Characteristic . | Value . |
|---|---|
| CRS maximum grade – n (%) | |
| 0 | 8 (15%) |
| 1 | 35 (67%) |
| 2 | 6 (12%) |
| 3 | 1 (2%) |
| 4 | 1 (2%) |
| 5 | 1 (2%) |
| Time to CRS onset (days) – median (range) | 1 (0–13) |
| Time to maximum severity CRS (days) – median (range) | 1 (0–13) |
| Duration of CRS (days) – median (range) | 3 (0–10) |
| ICANS maximum grade – n (%) | |
| 0 | 42 (81%) |
| 1 | 4 (8%) |
| 2 | 2 (4%) |
| 3 | 3 (6%) |
| 4 | 1 (2%) |
| 5 | 0 (0%) |
| Time to ICANS onset (days) – median (range) | 2.5 (0–8) |
| Time to maximum severity ICANS (days) – median (range) | 3.5 (0–15) |
| Duration of ICANS (days) – median (range) | 1.5 (1–27) |
| Treatment for toxicity – n (%) | |
| Steroid use | 18 (35%) |
| Tocilizumab use | 44 (85%) |
| Anakinra use | 1 (2%) |
| Day 30 response – n (%) | |
| ORR | 42 (84%) |
| CR or sCR | 18 (36%) |
| MRD negative | 9 (69%) |
| VGPR | 10 (20%) |
| PR | 14 (28%) |
| MRD negative | 19 (73%) |
| Day 90 response – n (%) | |
| ORR | 40 (89%) |
| CR or sCR | 20 (44%) |
| MRD negative | 14 (88%) |
| VGPR | 6 (13%) |
| PR | 14 (31%) |
| MRD negative | 23 (85%) |
| Best response in first 90 d – n (%) | |
| ORR | 46 (92%) |
| CR or sCR | 24 (48%) |
| MRD negative | 17 (81%) |
| VGPR | 6 (12%) |
| PR | 16 (32%) |
| MRD negative | 28 (78%) |
| Characteristic . | Value . |
|---|---|
| CRS maximum grade – n (%) | |
| 0 | 8 (15%) |
| 1 | 35 (67%) |
| 2 | 6 (12%) |
| 3 | 1 (2%) |
| 4 | 1 (2%) |
| 5 | 1 (2%) |
| Time to CRS onset (days) – median (range) | 1 (0–13) |
| Time to maximum severity CRS (days) – median (range) | 1 (0–13) |
| Duration of CRS (days) – median (range) | 3 (0–10) |
| ICANS maximum grade – n (%) | |
| 0 | 42 (81%) |
| 1 | 4 (8%) |
| 2 | 2 (4%) |
| 3 | 3 (6%) |
| 4 | 1 (2%) |
| 5 | 0 (0%) |
| Time to ICANS onset (days) – median (range) | 2.5 (0–8) |
| Time to maximum severity ICANS (days) – median (range) | 3.5 (0–15) |
| Duration of ICANS (days) – median (range) | 1.5 (1–27) |
| Treatment for toxicity – n (%) | |
| Steroid use | 18 (35%) |
| Tocilizumab use | 44 (85%) |
| Anakinra use | 1 (2%) |
| Day 30 response – n (%) | |
| ORR | 42 (84%) |
| CR or sCR | 18 (36%) |
| MRD negative | 9 (69%) |
| VGPR | 10 (20%) |
| PR | 14 (28%) |
| MRD negative | 19 (73%) |
| Day 90 response – n (%) | |
| ORR | 40 (89%) |
| CR or sCR | 20 (44%) |
| MRD negative | 14 (88%) |
| VGPR | 6 (13%) |
| PR | 14 (31%) |
| MRD negative | 23 (85%) |
| Best response in first 90 d – n (%) | |
| ORR | 46 (92%) |
| CR or sCR | 24 (48%) |
| MRD negative | 17 (81%) |
| VGPR | 6 (12%) |
| PR | 16 (32%) |
| MRD negative | 28 (78%) |
Clinical outcomes following idecabtagene vicleucel (ide-cel) infusion: For results regarding cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and treatment for toxicity, N = 52. For day-30 response and best response in first 90 days, N = 50 due to 1 patient not evaluable and 1 patient who died due to CRS at day 8. For day-90 response, N = 45 due to 3 patients who progressed prior to day-90 evaluation, 2 total patients not evaluable, and 2 total patients who died before day 90. For minimal residual disease (MRD) negative results, N is number of patients at that time who had MRD testing done (13 of CR/sCR patients at day 30; 26 for all responses at day 30; 16 of CR/sCR patients at day 90; 27 for all responses at day 90; 21 of CR/sCR patients for best response; and 36 for all best responses). ORR, overall response rate, calculated as patients with at least partial response (PR); CR, complete response; sCR, stringent complete response; VGPR, very good PR.